Cardiol Therapeutics A

Cardiol Therapeutics announced at the Canaccord Growth Conference that MAVERIC phase‑III data on prevention of recurrences after stopping rilonacept should be available in roughly seven months. The 110‑patient study aims for a 40% relative risk reduction; earlier phase‑II data showed a strong signal with 71% of patients remaining recurrence‑free on CardiolRx monotherapy. Management sees large market potential (IL‑1 blocker market >1 billion CAD), expects possible pricing levels of up to 60% of rilonacept, and is preparing a regulatory filing if results are positive; programs for myocarditis and heart failure (CRD‑38) are also underway. » More on de.investing.com

Cardiol Therapeutics announced publication of the phase II MAvERIC study in the Journal of the American Heart Association. CardiolRx led to pain reduction, decreased inflammation and fewer recurrences per year in patients with recurrent pericarditis, with a favorable safety profile. The stock trades at $1.06 with a market capitalization of $122 million; analyst targets range from $4.85 to $8.74. The phase III MAVERIC study is nearing completion of patient recruitment. » More on de.investing.com

Cardiol Therapeutics announces a live interview with CEO David Elsley in which the approval‑relevant phase‑III MAVERIC study of CardiolRx for recurrent pericarditis, the phase‑II results of the ARCHER study in acute myocarditis, and the development of CRD‑38 for heart failure will be discussed. A recording of the conversation will be made available afterwards on the company’s X channel and via Barchart. Cardiol Therapeutics focuses on anti‑inflammatory and antifibrotic therapies; CardiolRx is aimed at modulating the inflammasome signaling pathway. » More on de.investing.com